Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AADI NASDAQ:BCDA NASDAQ:FGEN NASDAQ:PEPG On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAADIAadi Bioscience$1.86-6.5%$1.81$1.21▼$3.81$45.94M0.68261,100 shs105,693 shsBCDABioCardia$1.70-20.9%$2.06$1.63▼$3.25$12.47M0.8538,294 shs679,888 shsFGENFibroGen$11.51-2.8%$9.32$4.50▼$21.94$47.88M0.7640,924 shs14,074 shsPEPGPepGen$1.94+22.0%$1.32$0.88▼$10.06$52.15M1.17358,042 shs3.19 million shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAADIAadi Bioscience0.00%+9.34%+24.38%-2.45%+10.56%BCDABioCardia+0.47%+2.87%+11.98%+1.90%-27.61%FGENFibroGen-1.58%+6.09%+24.76%+101.36%+0.77%PEPGPepGen+7.43%+6.71%+23.26%+12.77%-83.23%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAADIAadi Bioscience$1.86-6.5%$1.81$1.21▼$3.81$45.94M0.68261,100 shs105,693 shsBCDABioCardia$1.70-20.9%$2.06$1.63▼$3.25$12.47M0.8538,294 shs679,888 shsFGENFibroGen$11.51-2.8%$9.32$4.50▼$21.94$47.88M0.7640,924 shs14,074 shsPEPGPepGen$1.94+22.0%$1.32$0.88▼$10.06$52.15M1.17358,042 shs3.19 million shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAADIAadi Bioscience0.00%+9.34%+24.38%-2.45%+10.56%BCDABioCardia+0.47%+2.87%+11.98%+1.90%-27.61%FGENFibroGen-1.58%+6.09%+24.76%+101.36%+0.77%PEPGPepGen+7.43%+6.71%+23.26%+12.77%-83.23%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAADIAadi Bioscience 0.00N/AN/AN/ABCDABioCardia 3.50Strong Buy$25.001,370.59% UpsideFGENFibroGen 2.50Moderate Buy$43.00273.59% UpsidePEPGPepGen 2.50Moderate Buy$7.25273.71% UpsideCurrent Analyst Ratings BreakdownLatest BCDA, AADI, FGEN, and PEPG Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/9/2025PEPGPepGenGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$6.008/7/2025FGENFibroGenHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$43.00(Data available from 9/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAADIAadi Bioscience$25.07M1.83N/AN/A$4.29 per share0.43BCDABioCardia$60K164.33N/AN/A$0.18 per share9.44FGENFibroGen$29.62M1.57N/AN/A($50.89) per share-0.23PEPGPepGenN/AN/AN/AN/A$3.64 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAADIAadi Bioscience-$65.76M-$2.35N/AN/AN/A-246.06%-71.87%-57.28%11/4/2025 (Estimated)BCDABioCardia-$7.95M-$1.85N/AN/AN/AN/A-19,117.42%-246.92%11/11/2025 (Estimated)FGENFibroGen-$47.58M-$0.38N/AN/AN/A-3.86%N/A-27.34%11/11/2025 (Estimated)PEPGPepGen-$89.98M-$2.96N/AN/AN/AN/A-92.51%-70.39%11/6/2025 (Estimated)Latest BCDA, AADI, FGEN, and PEPG EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/11/2025Q2 2025BCDABioCardia-$0.50-$0.40+$0.10-$0.40N/AN/A8/11/2025Q2 2025FGENFibroGen-$2.25-$3.38-$1.13-$1.88$2.88 million$1.30 million8/7/2025Q2 2025PEPGPepGen-$0.85-$0.70+$0.15-$0.70N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAADIAadi BioscienceN/AN/AN/AN/AN/ABCDABioCardiaN/AN/AN/AN/AN/AFGENFibroGenN/AN/AN/AN/AN/APEPGPepGenN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAADIAadi BioscienceN/A4.894.54BCDABioCardiaN/A0.330.33FGENFibroGenN/A1.041.02PEPGPepGenN/A4.744.74Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAADIAadi Bioscience52.08%BCDABioCardia20.57%FGENFibroGen72.71%PEPGPepGen58.01%Insider OwnershipCompanyInsider OwnershipAADIAadi Bioscience37.30%BCDABioCardia20.00%FGENFibroGen1.98%PEPGPepGen4.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAADIAadi Bioscience4024.70 million15.49 millionOptionableBCDABioCardia405.80 million4.64 millionOptionableFGENFibroGen5704.04 million3.96 millionOptionablePEPGPepGen3032.80 million31.29 millionNot OptionableBCDA, AADI, FGEN, and PEPG HeadlinesRecent News About These CompaniesGuggenheim Initiates Coverage of PepGen (PEPG) with Buy RecommendationSeptember 10, 2025 | msn.comPepGen (NASDAQ:PEPG) Now Covered by Analysts at GuggenheimSeptember 10, 2025 | americanbankingnews.comPepGen initiated with a Buy at GuggenheimSeptember 9, 2025 | msn.comFINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of PepGenAugust 11, 2025 | businesswire.comFaruqi & Faruqi Reminds PepGen Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of August 11, 2025 - PEPGAugust 9, 2025 | prnewswire.comLevi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of PepGen Inc.(PEPG) ShareholdersAugust 8, 2025 | globenewswire.comPepGen Reports Second Quarter 2025 Financial Results and Recent Corporate HighlightsAugust 8, 2025 | finance.yahoo.comPepGen Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before August 8, 2025 to Discuss Your Rights - PEPGAugust 8, 2025 | prnewswire.comPEPGEN (PEPG) FINAL DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds PepGen Investors of the August 8th Deadline and Encourages Investors to Contact the FirmAugust 7, 2025 | globenewswire.comLost Money on PepGen Inc. (PEPG)? Join Class Action Suit Seeking Recovery – Contact The Gross Law FirmAugust 7, 2025 | globenewswire.comPepGen Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. August 8, 2025 Deadline to file Lead Plaintiff Motion.August 7, 2025 | globenewswire.comPEPG INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that PepGen Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action LawsuitAugust 7, 2025 | globenewswire.comPEPG Investors Have Opportunity to Lead PepGen Inc. Securities Fraud Lawsuit with the Schall Law FirmAugust 7, 2025 | prnewswire.comPEPG DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Encourages PepGen Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important August 8 Deadline in Securities Class Action – PEPGAugust 6, 2025 | globenewswire.comPomerantz Law Firm Announces the Filing of a Class Action Against PepGen Inc. and Certain Officers - PEPGAugust 6, 2025 | prnewswire.comPEPGEN (PEPG) URGENT DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds PepGen Investors of the August 8th Deadline and Encourages Investors to Contact the FirmAugust 5, 2025 | globenewswire.comPepGen Inc. Investors: Please contact the Portnoy Law Firm to recover your losses; August 8, 2025 Deadline to file Lead Plaintiff MotionAugust 5, 2025 | globenewswire.comLevi & Korsinsky Notifies PepGen Inc. Investors of a Class Action Lawsuit and Upcoming Deadline – PEPGAugust 5, 2025 | globenewswire.comPomerantz Law Firm Announces the Filing of a Class Action Against PepGen Inc. and Certain Officers – PEPGAugust 5, 2025 | globenewswire.comDEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of PepGenAugust 5, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeBCDA, AADI, FGEN, and PEPG Company DescriptionsAadi Bioscience NASDAQ:AADI$1.86 -0.13 (-6.53%) As of 09/15/2025Aadi Bioscience, Inc., a biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug product candidate comprises FYARRO, a form of sirolimus protein-bound particles for injectable suspension for the treatment in adult patients with advanced unresectable or metastatic malignant PEComa. The company is also involved in evaluating FYARRO in cancers, including indications targeting specific genomic alterations that activate the mTOR pathway. Aadi Bioscience, Inc. was incorporated in 2007 and is headquartered in Pacific Palisades, California.BioCardia NASDAQ:BCDA$1.70 -0.45 (-20.93%) Closing price 04:00 PM EasternExtended Trading$1.72 +0.03 (+1.47%) As of 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia. The company is also developing an allogeneic cells therapy platform, which is an investigational culture expanded bone marrow derived mesenchymal cell therapy in Phase I/II trial to treat ischemic heart failure and acute respiratory distress syndrome. In addition, it offers the Helix biotherapeutic delivery system for minimally invasive targeted delivery of biologic agents to the heart; and Morph deflectable guides and sheaths. The company has collaboration agreements with CellProthera in the development of ProtheraCytes, which is currently under Phase II trial for the treatment of acute myocardial infarction. BioCardia, Inc. is based in Sunnyvale, California.FibroGen NASDAQ:FGEN$11.51 -0.33 (-2.79%) Closing price 04:00 PM EasternExtended Trading$11.70 +0.19 (+1.65%) As of 05:13 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.PepGen NASDAQ:PEPG$1.94 +0.35 (+22.01%) Closing price 04:00 PM EasternExtended Trading$1.95 +0.01 (+0.52%) As of 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. Its lead product candidate is PGN-EDO51, an EDO peptide that is in Phase 2 clinical trial to treat Duchenne muscular dystrophy (DMD) patients. The company is also developing PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 1 clinical trial for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD. PepGen Inc. was founded in 2018 and is based in Boston, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Resideo Technologies: Institutional Activity Signals 30% Upside Lululemon’s Sell-Off Looks Overdone: A Contrarian Case Palantir’s Commercial Growth Story Is Just Getting Started How Bath & Body Works Is a Perfect Example of a Value Stock The Applied Digital Breakout Is Only the Beginning $100 Million Buyback in Upwork Stock Follows a Strong Quarter Uranium Energy Stock Has Momentum—and More Upside Ahead Why Opendoor Stock Is Soaring—and May Just Be Starting Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
